Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Raw Materials: 2021-2025

Historic Raw Materials for Fortress Biotech (FBIO) over the last 4 years, with Mar 2025 value amounting to $2.8 million.

  • Fortress Biotech's Raw Materials fell 32.82% to $2.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.8 million, marking a year-over-year decrease of 32.82%. This contributed to the annual value of $3.2 million for FY2024, which is 31.12% down from last year.
  • Latest data reveals that Fortress Biotech reported Raw Materials of $2.8 million as of Q1 2025, which was down 12.14% from $3.2 million recorded in Q4 2024.
  • Fortress Biotech's Raw Materials' 5-year high stood at $8.4 million during Q1 2022, with a 5-year trough of $2.8 million in Q1 2025.
  • Over the past 3 years, Fortress Biotech's median Raw Materials value was $4.2 million (recorded in 2024), while the average stood at $4.2 million.
  • Its Raw Materials has fluctuated over the past 5 years, first skyrocketed by 46.89% in 2022, then tumbled by 34.53% in 2023.
  • Quarterly analysis of 5 years shows Fortress Biotech's Raw Materials stood at $5.6 million in 2021, then grew by 15.83% to $6.5 million in 2022, then fell by 28.11% to $4.6 million in 2023, then slumped by 31.12% to $3.2 million in 2024, then slumped by 32.82% to $2.8 million in 2025.
  • Its Raw Materials stands at $2.8 million for Q1 2025, versus $3.2 million for Q4 2024 and $3.6 million for Q3 2024.